Table 3.
Coronary Outcomes Among Women in the Estrogen Plus Progestin and Estrogen Alone Women's Health Initiative[8,11]
| Estrogen Plus Progestin (HT) | Estrogen Alone (ET) | |||
|---|---|---|---|---|
| Participants HT Group (N=8506), Placebo (N=8102) | ParticipantsET (N= 5310), Placebo (N=5429) | |||
| Variable | HT HR | HT nCI | ET HR | ET nCI |
| CHD total | 1.24 | 1.00-1.54 | 0.91 | 0.75-1.12 |
| CHD 50-59 yrs | 1.27 | 0.8-2.1* | 0.56 | 0.30-1.03 |
| CHD 60-69 yrs | 1.05 | 0.78-1.4* | 0.92 | 0.69-1.23 |
| CHD 70-79 yrs | 1.44 | 0.89-2.0* | 1.04 | 0.75-1.44 |
| CHD death | 1.1 | 0.70-1.75 | 0.94 | 0.65-1.36 |
| Nonfatal MI | 1.28 | 1.00-1.63 | 0.89 | 0.70-1.12 |
Note: Therapy is compared with placebo in healthy postmenopausal women.
CHD = coronary heart disease; HR = hazard ratio; MI = myocardial infarction; nCI = nominal confidence interval* = Numerical data not stated but number extrapolated from Figure 3.[8]